Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Up 34.8% in November

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) saw a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 138,600 shares, a growth of 34.8% from the November 15th total of 102,800 shares. Based on an average trading volume of 4,269,100 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Bank of America raised shares of Bayer Aktiengesellschaft from an "underperform" rating to a "neutral" rating in a research report on Friday, September 6th. One analyst has rated the stock with a sell rating and five have given a hold rating to the company. According to data from MarketBeat, Bayer Aktiengesellschaft currently has a consensus rating of "Hold".

Bayer Aktiengesellschaft Trading Down 1.3 %

OTCMKTS BAYRY traded down $0.07 on Friday, reaching $5.16. The stock had a trading volume of 896,226 shares, compared to its average volume of 1,400,476. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.81 and a current ratio of 1.32. The firm has a fifty day moving average of $6.22 and a two-hundred day moving average of $7.06. Bayer Aktiengesellschaft has a 1-year low of $4.94 and a 1-year high of $9.79.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.10). The company had revenue of $10.96 billion for the quarter. Bayer Aktiengesellschaft had a positive return on equity of 16.90% and a negative net margin of 2.02%. Research analysts anticipate that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.